The vaccine, developed by GlaxoSmithKline, has won the support of an FDA advisory panel. The panel found the vaccine was effective and safe enough to use against the N5N1 avian flu. The strain is rare in humans, but very dangerous.
The World Health Organization says 608 people have been infected by the virus worldwide since 2003, more than half of them died.
Final FDA approval is expected later this year.